Dentone, C;
Di Biagio, A;
Cozzi Lepri, A;
Fenoglio, D;
Filaci, G;
Lichtner, M;
Carrara, S;
... ICONA Foundation Study Group, .; + view all
(2018)
Inflammatory effects of atazanavir/ritonavir versus darunavir/ritonavir in treatment naïve, HIV-1-infected patients.
HIV Clinical Trials
, 19
(4)
pp. 158-162.
10.1080/15284336.2018.1488453.
Preview |
Text
Dentone_HCT_dibiagio_AD_1 27.05.2018. docAD.pdf - Accepted Version Download (327kB) | Preview |
Abstract
BACKGROUND: Limited studies have compared the impact of different antiretroviral regimens on soluble markers of inflammation with discordant results. METHODS: In this prospective study, treatment naïve HIV-1-infected patients were included if they started their current regimen with atazanavir/ritonavir (ATV/r) (N = 73, Group 1) or darunavir/ritonavir (DRV/r) (N = 85, Group 2) plus tenofovir/emtricitabine. The analysis of IL-6, MCP-1, sCD163, VCAM-1, ox-LDL, and adiponectine was performed on two stored plasma samples, the first prior to antiretroviral therapy initiation and the second one year after initiation. RESULTS: The results of our analysis show a difference in ox-LDL between the two groups with higher mean (SD) values in ATV/r based group 608.5 ± 137.4 versus 519.1 ± 119.6 in DRV/r group, after controlling for baseline levels of ox-LDL as well as other potential confounding factors controlled by means of matching design or linear regression modelling. CONCLUSIONS: Our analysis provides further data examining the association between the modulation of vascular inflammatory and of activation markers with specific protease inhibitors-based treatments over one year of exposure to these drugs. The data show little evidence for an association, supporting the notion that antiretroviral regimens has generally poor efficiency in downregulating these soluble markers.
| Type: | Article |
|---|---|
| Title: | Inflammatory effects of atazanavir/ritonavir versus darunavir/ritonavir in treatment naïve, HIV-1-infected patients |
| Location: | England |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1080/15284336.2018.1488453 |
| Publisher version: | https://doi.org/10.1080/15284336.2018.1488453 |
| Language: | English |
| Additional information: | This version is the author accepted manuscript. For information on re-use, please refer to the publisher’s terms and conditions. |
| Keywords: | Vascular inflammation, activation markers, first-line antiretroviral therapy, atazanavir, darunavir, HIV |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > Institute for Global Health UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > Institute for Global Health > Infection and Population Health |
| URI: | https://discovery.ucl.ac.uk/id/eprint/10061715 |
Archive Staff Only
 |
View Item |
